Page last updated: 2024-09-04

canertinib dihydrochloride and canertinib

canertinib dihydrochloride has been researched along with canertinib in 1 studies

Compound Research Comparison

Studies
(canertinib dihydrochloride)
Trials
(canertinib dihydrochloride)
Recent Studies (post-2010)
(canertinib dihydrochloride)
Studies
(canertinib)
Trials
(canertinib)
Recent Studies (post-2010) (canertinib)
31136124965

Protein Interaction Comparison

ProteinTaxonomycanertinib dihydrochloride (IC50)canertinib (IC50)
Epidermal growth factor receptorHomo sapiens (human)0.0068
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.0757
Tyrosine-protein kinase BlkHomo sapiens (human)0.0395
Cytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)0.324
Tyrosine-protein kinase JAK3Homo sapiens (human)2.94
Dipeptidyl peptidase 1Homo sapiens (human)2.7
Tyrosine-protein kinase BTKHomo sapiens (human)0.185
Tyrosine-protein kinase ITK/TSKHomo sapiens (human)5.65
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)0.0103

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bridges, AJ; Denny, WA; Elliott, WL; Fry, DW; McNamara, DJ; Nelson, JM; Roberts, BJ; Sherwood, V; Showalter, HD; Smaill, JB; Vincent, PW; Zhou, H1

Other Studies

1 other study(ies) available for canertinib dihydrochloride and canertinib

ArticleYear
Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.
    Journal of medicinal chemistry, 2001, Feb-01, Volume: 44, Issue:3

    Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Inhibitory Concentration 50; Mice; Phosphorylation; Pyrimidines; Quinazolines; Solubility; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured

2001